POZ June 2018
POZ June 2018
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
Don’t Shoot the Messenger
In this essay, a long-term HIV survivor links past AIDS activism to current efforts to prevent gun violence.
Advocacy in Action
During AIDSWatch 2018, HIV advocates visit Capitol Hill to lobby for the needs of people living with and at risk for HIV. [VIDEO]
Unconditional Love
A collection of art showcases the powerful bond between us and our pets.
Editor’s Letter
Strong Enough
Our June cover story links past AIDS activism to current efforts to prevent gun violence.
POZ Q+A
Bold Vision
After nearly two decades, the Black AIDS Institute faces the future with new leadership and expanded services.
POZ Planet
Why Move AIDS 2020 Out of the United States?
Advocates want the conference relocated.
Love and Loss
A heart-wrenching POZ Stories installment
Meet the New Director of the CDC
Robert R. Redfield, MD, is a longtime HIV researcher. But he’s also controversial.
Aging, but Not So Gracefully
In After Louie, Alan Cumming is an older AIDS activist with issues.
Voices
Anti-LGBT Stances
AIDS United calls out actions by the Trump administration that have harmed people living with HIV and LGBT people.
Victor or Victim?
POZ deputy editor Trent Straube interviews John-Manuel Andriote about his latest book, “Stonewall Strong.”
Everyday
Everyday — June 2018
Here are some important dates in AIDS history.
Spotlight
Get Tested
HIV testing news pops up in our social media feeds.
Research Notes
Prevention: Low-Dose PrEP
Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.
Treatment: Naltrexone
This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.
Cure: Delaying Rebound
Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.
Concerns: PrEP Disparities
The CDC reports that PrEP use is low among Blacks and Latinos.
Care and Treatment
New Salvage Treatment
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
Not Enough People With HIV Receive Proper Cancer Treatment
An estimated 7,760 HIV-positive U.S. residents were diagnosed with cancer in 2010.
FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
Chance of Curing Hep C Is Lower Among Some Living With HIV
People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.
Heroes
“Why Be Cruel?”
AIDS activist and author Sarah Schulman explores HIV criminalization in “Conflict Is Not Abuse.”
